{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:15:47Z","timestamp":1784754947376,"version":"3.55.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aims to analyze potential adverse events (AEs) associated with ripretinib and sunitinb in gastrointestinal stromal tumor (GIST) treatment using data from the FDA Adverse Event Reporting System (FAERS). The findings provide insights for future research to improve the safety and clinical management of ripretinib and sunitinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adverse Drug Event (ADE) reports related to ripretinib and sunitinib were extracted from the FAERS database, covering the period from Q2 2020 to Q4 2024 and Q1 2006 to Q4 2024, respectively. ADEs were classified and described according to Preferred Terms (PTs) and System Organ Classes (SOCs) in the Medical Dictionary for Regulatory Activities (MedDRA). Disproportionality analysis, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS), was employed to identify significant signals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 3,636 and 34,768 ADE reports related to ripretinib and sunitinib were identified using four disproportionality analysis methods. The top five ADR signals for ripretinib include hepatic embolization, tumor compression, hyperkeratosis, tumor excision and tumor pain. For sunitinib, the five strongest ADR signals are metastatic renal cell carcinoma, diffuse uveal melanocytic proliferation, renal cancer metastasis, connective tissue neoplasm and salivary gland fistula. Both drugs share significant ADRs including palmar-plantar erythrodysesthesia syndrome, disease progression and hyperkeratosis. Furthermore, subgroup analysis was conducted to explore sex difference in ripretinib and sunitinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study validated known AEs and identified new potential safety signals associated with ripretinib and sunitinib in GIST treatment. These findings contribute to the understanding of ripretinib and sunitinib, providing valuable evidence for improving its clinical use.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1561937","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T05:22:42Z","timestamp":1750915362000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Gastrointestinal stromal tumors with the use of ripretinib and sunitinib: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)"],"prefix":"10.3389","volume":"16","author":[{"given":"Xinzhen","family":"Che","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet, Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"107498","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"Chen","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s40265-020-01348-2","article-title":"Ripretinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1111\/jdv.20197","article-title":"Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023","volume":"39","author":"Godfrey","year":"2025","journal-title":"J. Eur. Acad. Dermatol Venereol. JEADV"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.2217\/fon-2022-0226","article-title":"Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval","volume":"18","author":"Goggin","year":"2022","journal-title":"Future Oncol. lond Engl."},{"key":"B7","doi-asserted-by":"publisher","first-page":"20601","DOI":"10.1038\/s41598-022-23726-4","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib","volume":"12","author":"Guo","year":"2022","journal-title":"Sci. Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.tplants.2023.03.005","article-title":"Significance of nitrogen-fixing actinorhizal symbioses for restoration of depleted, degraded, and contaminated soil","volume":"28","author":"Hu","year":"2023","journal-title":"Trends Plant Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1200\/JCO.20.00522","article-title":"Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: a phase I study of ripretinib","volume":"38","author":"Janku","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"100929","DOI":"10.1016\/j.drup.2023.100929","article-title":"Sunitinib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers","volume":"67","author":"Jin","year":"2023","journal-title":"Drug Resist Updat. Rev. Comment Antimicrob. Anticancer Chemother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13045-020-01026-6","article-title":"The management of metastatic GIST: current standard and investigational therapeutics","volume":"14","author":"Kelly","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41571-022-00606-4","article-title":"New treatment strategies for advanced-stage gastrointestinal stromal tumours","volume":"19","author":"Klug","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2412234","article-title":"Exploring SGLT-2 inhibitors and sarcopenia in FAERS: a post-marketing surveillance study","author":"Kuai","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-22-2400","article-title":"FDA approval summary: ripretinib for advanced gastrointestinal stromal tumor","volume":"29","author":"Kumar","year":"2023","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40360-025-00856-9","article-title":"Drug-related macular edema: a real-world FDA adverse event reporting system database study","volume":"26","author":"Li","year":"2025","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1158\/1078-0432.CCR-22-3613","article-title":"Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer","volume":"29","author":"Lin","year":"2023","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1758835920986498","DOI":"10.1177\/1758835920986498","article-title":"Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward","volume":"13","author":"Lostes-Bardaji","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/14740338.2024.2419989","article-title":"Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology","volume":"24","author":"Luo","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1093\/bjd\/ljad167","article-title":"Defective cathepsin Z affects EGFR expression and causes autosomal dominant palmoplantar keratoderma","volume":"189","author":"Malovitski","year":"2023","journal-title":"Br. J. Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/13543784.2021.1857363","article-title":"Systemic therapy of advanced\/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib","volume":"30","author":"Mohammadi","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1200\/JCO.23.01197","article-title":"KIT ATP-Binding pocket\/activation loop mutations in GI stromal tumor: emerging mechanisms of kinase inhibitor escape","volume":"42","author":"M\u00fchlenberg","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e26006","DOI":"10.7759\/cureus.26006","article-title":"Verruca vulgaris eruption arising in the setting of a tyrosine kinase inhibitor","volume":"14","author":"Muskat","year":"2022","journal-title":"Cureus"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1251961","DOI":"10.3389\/fphar.2024.1251961","article-title":"A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor","volume":"15","author":"Pan","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"101582","DOI":"10.1016\/j.ajoc.2022.101582","article-title":"Presumed bilateral diffuse uveal melanocytic proliferation - a case report and review of literature","volume":"27","author":"Parakh","year":"2022","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3390\/biomedicines8110490","article-title":"Ocular paraneoplastic syndromes","volume":"8","author":"Prze\u017adziecka-Do\u0142yk","year":"2020","journal-title":"Biomedicines"},{"key":"B26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.18773\/austprescr.2021.025","article-title":"Ripretinib for gastrointestinal stromal tumours","volume":"44","year":"2021","journal-title":"Aust. Prescr."},{"key":"B27","doi-asserted-by":"publisher","first-page":"105463","DOI":"10.1016\/j.phrs.2021.105463","article-title":"Properties of FDA-Approved small molecule protein kinase inhibitors: a 2021 update","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/s41433-021-01676-x","article-title":"Paraneoplastic ocular syndrome: a pandora\u2019s box of underlying malignancies","volume":"36","author":"Sarkar","year":"2022","journal-title":"Eye lond Engl."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1200\/JCO.22.01406","article-title":"Ripretinib and the failure to advance GI stromal tumor therapy in the age of precision medicine","volume":"40","author":"Schwartz","year":"2022","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2174\/1389200221666201019143252","article-title":"Tumor angiogenesis and VEGFR-2: mechanism, pathways and current biological therapeutic interventions","volume":"22","author":"Shah","year":"2021","journal-title":"Curr. Drug Metab."},{"key":"B31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canep.2015.10.031","article-title":"Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies","volume":"40","author":"S\u00f8reide","year":"2016","journal-title":"Cancer Epidemiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"691686","DOI":"10.3389\/fmed.2021.691686","article-title":"Bilateral diffuse uveal melanocytic proliferation secondary to rectal adenocarcinoma: a case report and literature review","volume":"8","author":"Tong","year":"2021","journal-title":"Front. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1226086","DOI":"10.3389\/fphar.2023.1226086","article-title":"Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system","volume":"14","author":"Xiong","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13293-023-00526-7","article-title":"Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and sunitinib response in patients with clear cell renal cell carcinoma","volume":"14","author":"Yuan","year":"2023","journal-title":"Biol. Sex. Differ."},{"key":"B36","doi-asserted-by":"publisher","first-page":"17562848211008177","DOI":"10.1177\/17562848211008177","article-title":"Ripretinib for the treatment of advanced gastrointestinal stromal tumor","volume":"14","author":"Zalcberg","year":"2021","journal-title":"Ther. Adv. Gastroenterol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1007\/s12325-023-02576-0","article-title":"Large-scale, multicenter, prospective registry study of ripretinib in advanced GIST: a real-world study from China","volume":"40","author":"Zhang","year":"2023","journal-title":"Adv. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1277734","DOI":"10.3389\/fimmu.2023.1277734","article-title":"Dupilumab and the potential risk of eosinophilic pneumonia: case report, literature review, and FAERS database analysis","volume":"14","author":"Zhou","year":"2023","journal-title":"Front. Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.1038\/s41598-025-89272-x","article-title":"Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database","volume":"15","author":"Zhu","year":"2025","journal-title":"Sci. Rep."}],"updated-by":[{"DOI":"10.3389\/fphar.2025.1689499","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1561937\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T14:30:08Z","timestamp":1757428208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1561937\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":39,"alternative-id":["10.3389\/fphar.2025.1561937"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1561937","relation":{"correction":[{"id-type":"doi","id":"10.3389\/fphar.2025.1689499","asserted-by":"object"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"article-number":"1561937"}}